Physician profile
Pawan Kumar
NPI 1972541829
$2,048.44
in general payments reported to CMS, 2019-2025
32 companies · $268 in 2025
The $268 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $256 · 2021: $535 · 2022: $213 · 2023: $367 · 2024: $271 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.06 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $313.26 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Mannkind Corporation | $189.69 | 2019-2025 | |
| Corcept Therapeutics | $171.12 | 2023-2024 | Korlym |
| Glaxosmithkline, LLC. | $141.08 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $136.06 | 2020-2024 | Rybelsus, Ozempic |
| Genentech USA, INC. | $125.00 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $123.11 | 2020-2023 | Farxiga |
| Abbvie INC. | $115.52 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $109.09 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.00 | 2019-2022 | |
| Insulet Corporation | $56.79 | 2021 | |
| Amgen INC. | $43.95 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $41.07 | 2020-2023 | |
| Exact Sciences Corporation | $36.76 | 2024 | Cologuard Collection Kit |
| Ascendis Pharma Endocrinology INC | $30.85 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $29.27 | 2025 | Isturisa |
| Amryt Pharma Holdings Ltd | $25.24 | 2022 | |
| Tandem Diabetes Care, INC. | $24.60 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Baxter Healthcare | $21.30 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Idorsia Pharmaceuticals US INC | $20.38 | 2023 | Quviviq |
| Shield Therapeutics INC | $20.12 | 2025 | |
| Ascensia Diabetes Care US INC. | $19.74 | 2024 | |
| Kyowa Kirin, INC. | $19.42 | 2023 | Crysvita |
| Radius Health, INC. | $19.04 | 2023 | |
| Gilead Sciences, INC. | $18.95 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $18.63 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $18.59 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.28 | 2024 | Trintellix |
| Dexcom, INC. | $17.85 | 2021 | |
| Viiv Healthcare Company | $14.03 | 2025 | Dovato |
| Zealand Pharma US, INC. | $11.84 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pawan Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.